Alnylam Pharmaceuticals Inc (NASDAQ: ALNY)’s stock price has soared by 2.04 in relation to previous closing price of 298.58. Nevertheless, the company has seen a loss of -1.08% in its stock price over the last five trading days. zacks.com reported 2025-06-10 that ALNY gains approval to expand Amvuttra’s label in the EU, boosting its position as the only RNAi therapy for ATTR-CM.
Is It Worth Investing in Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) Right Now?
Additionally, the 36-month beta value for ALNY is 0.21. There are mixed opinions on the stock, with 12 analysts rating it as a “buy,” 12 rating it as “overweight,” 7 rating it as “hold,” and 1 rating it as “sell.”
The public float for ALNY is 124.67M and currently, short sellers hold a 2.77% ratio of that float. The average trading volume of ALNY on June 13, 2025 was 1.03M shares.
ALNY’s Market Performance
The stock of Alnylam Pharmaceuticals Inc (ALNY) has seen a -1.08% decrease in the past week, with a 14.17% rise in the past month, and a 26.03% gain in the past quarter. The volatility ratio for the week is 1.49%, and the volatility levels for the past 30 days are at 1.93% for ALNY. The simple moving average for the past 20 days is 2.74% for ALNY’s stock, with a 15.79% simple moving average for the past 200 days.
Analysts’ Opinion of ALNY
Many brokerage firms have already submitted their reports for ALNY stocks, with Redburn Atlantic repeating the rating for ALNY by listing it as a “Buy.” The predicted price for ALNY in the upcoming period, according to Redburn Atlantic is $353 based on the research report published on March 31, 2025 of the current year 2025.
JP Morgan, on the other hand, stated in their research note that they expect to see ALNY reach a price target of $328, previously predicting the price at $280. The rating they have provided for ALNY stocks is “Overweight” according to the report published on March 24th, 2025.
ALNY Trading at 13.47% from the 50-Day Moving Average
After a stumble in the market that brought ALNY to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -1.79% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ALNY starting from Greenstreet Yvonne, who sale 31,640 shares at the price of $304.39 back on May 30 ’25. After this action, Greenstreet Yvonne now owns 48,948 shares of Alnylam Pharmaceuticals Inc, valued at $9,630,902 using the latest closing price.
Greenstreet Yvonne, the Chief Executive Officer of Alnylam Pharmaceuticals Inc, sale 19,297 shares at $306.00 during a trade that took place back on Jun 02 ’25, which means that Greenstreet Yvonne is holding 48,948 shares at $5,904,882 based on the most recent closing price.
Stock Fundamentals for ALNY
Current profitability levels for the company are sitting at:
- -0.05 for the present operating margin
- 0.86 for the gross margin
The net margin for Alnylam Pharmaceuticals Inc stands at -0.11. The total capital return value is set at -0.04.
Based on Alnylam Pharmaceuticals Inc (ALNY), the company’s capital structure generated 0.92 points at debt to capital in total, while cash flow to debt ratio is standing at -0.03. The debt to equity ratio resting at 11.28. The interest coverage ratio of the stock is -0.79.
Currently, EBITDA for the company is -178.85 million with net debt to EBITDA at -1.85. When we switch over and look at the enterprise to sales, we see a ratio of 17.04. The receivables turnover for the company is 5.62for trailing twelve months and the total asset turnover is 0.56. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.04.
Conclusion
In conclusion, Alnylam Pharmaceuticals Inc (ALNY) has seen better performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
